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Abstract.  The identification of specific cell surface 
glycoprotein receptors for Arg-Gly-Asp-containing ex- 
tracellular matrix proteins such as fibronectin has fo- 
cused attention on the role of gangliosides in this pro- 
cess.  Is their involvement dependent or independent of 
the protein receptors? In attachment assays with cells 
from a  human melanoma cell line, titration experi- 
ments with an antibody (Mel 3) with specificity for 
the disialogangliosides GD2 and GD3,  used together 
with a  synthetic peptide containing the cell binding se- 
quence Arg-Gly-Asp, show that their joint effect is 
synergistic. Both the Mel 3 antibody and the synthetic 
peptide individually cause rapid detachment of mela- 
noma cells from fibronectin substrate but, when used 
together, much smaller concentations of both are re- 
quired to achieve the same effect. The Mel 3 antibody 
was not nonspecifically reducing receptor binding to 
the Arg-Gly-Asp sequence since, in binding assays 
with radiolabeled peptide performed with cells in sus- 
pension, very little peptide is bound by the melanoma 
cells under these conditions but addition of Mel 3,  an 
antibody of IgM isotype, causes a  two- to threefold in- 
crease in specific binding. The simplest interpretation 
of these data is that the Mel 3 antibody is causing 
sufficient clustering of membrane gangliosides in local 
areas and producing a  favorably charged environment 
to facilitate peptide binding by specific glycoprotein 
receptors. 
understanding of cell attachment to extracellular ma- 
trix proteins will provide insights into such process- 
es as cell migration and spreading, and tissue inva- 
sion by tumor cells.  For this reason,  the mechanisms by 
which different cells attach to fibronectin have been much 
studied and it is now clear that more than one interaction is 
involved.  Gangliosides have  been  suggested as  candidate 
receptors  for  fibronectin  since  their  addition  to  cultures 
caused rounding up and detachment of cells from the fibro- 
nectin substrate (24, 29, 47). Also, the insertion of ganglio- 
sides into the membranes of ganglioside-deficient cells en- 
abled them to bind fibronectin on the cell surface (40), and 
mAbs directed against determinants on the carbohydrates of 
the gangliosides GD2 and GD3 (41) prevented the attachment 
of melanoma cells to extracellular matrix proteins including 
fibronectin (12, 45). 
In another approach, Pierschbacher and colleagues iden- 
tified a peptide within the cell-binding domain of fibronectin 
that mediated the cell attachment activity of this molecule 
(31-33),  and Hayman et al. (18) and Yamada and Kennedy 
(46) went on to demonstrate that peptides containing the se- 
quence  arginyl-glycyl-aspartic acid  (Arg-Gly-Asp)  caused 
detachment of cultured cells from their substratum and pre- 
vented baby hamster kidney and Chinese hamster ovary cells 
from spreading on fibronectin substrates. From this informa- 
tion, Pytela et al. (35) were able to identify a specific glyco- 
protein receptor of ~140 kD on osteosarcoma cells and rat 
fibroblasts. It is now apparent that the fibronectin receptor 
thus isolated is but one of a family of structurally similar pro- 
teins that bind to Arg-Gly-Asp sequences contained within a 
variety of extracellular matrix proteins (reviewed in refer- 
ences 21  and 37). 
Within the fibronectin molecule there is an additional do- 
main that also appears to be involved in cell attachment. This 
domain is located towards the carboxy-terminal end of the A 
chain, which contains heparin binding activity (27), and high 
levels of Arg-Gly-Asp in solution have little effect on cells ad- 
hering to fragments containing this heparin-binding domain 
(27).  Binding of this fragment, however,  did not promote 
melanoma cell motility (27),  indicating that cell binding to 
different domains of the fibronectin molecule may result in 
different functions. The relationship between the ganglioside 
"receptor" and other receptors  is uncertain.  The  negative 
charges on the sialic acid moieties of GD2 and GD3 could 
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charged residues present in the type III homologies of the 
fibronectin molecule (30,  39).  Alternatively, Cheresh and 
Klier (10) have suggested that, for optimal cell adhesion, the 
active redistribution of  gangliosides into discrete areas of  cell 
attachment may cause synergism with cell surface receptors 
by creating an appropriate electrostatic environment. 
The present study presents evidence supporting this con- 
cept.  We show that an mAb that binds to GD2 and GD3 
inhibits attachment and, when used in relatively high con- 
centrations,  causes  detachment of melanoma  cells  from 
fibronectin substrates.  At low concentrations the antibody 
acts synergistically with a synthetic peptide containing the 
Arg-Gly-Asp sequence such that concentrations of antibody 
or peptide, which individually had no effect on attachment, 
together caused rapid  loss  of adhesion by the melanoma 
cells. In addition, we used a synthetic peptide containing the 
Arg-Gly-Asp sequence and a radioiodinated tyrosine residue 
to  demonstrate that melanoma cells  in  suspension bound 
only weakly to the peptide. However,  when the cells were 
reacted with the IgM mAb with specificity for GD2/GD3, 
this binding was increased severalfold. We favor the interpre- 
tation that the IgM antibody against GD2/GD3 was causing 
localized clustering (patching) of the gangliosides to provide 
favorable areas for attachment of the peptide to specific gly- 
coprotein receptors. 
Materials and Methods 
Cell Cultures 
The melanoma cell lines used in this study have been maintained in our lab- 
oratory  for  several  years  and  have  been  demonstrated  to  be  free  of 
mycoplasma contamination. The LiBr line was maintained in RPMI 1640 
medium supplemented with 10% heat-inactivated FCS (Flow Laboratories, 
Irvine, Scotland), glutamine (2 mM), 2-mercaptoethanol (5  x  10  -5 M), 
penicillin (100 I.tg/ml), and streptomycin (100 I.tg/ml). The cells were regu- 
larly passaged at subconfluence by detaching the adherent ceils by vigorous 
pipetting. 
Reagents 
Fibronectin was prepared from human plasma as described below or was 
purchased from Sigma Chemical Co.  (St.  Louis,  MO).  Iodoheads were 
from  Pierce Chemical  Co.  (Rockford,  IL).  F(ab')2  fragments of FITC- 
labeled sheep anti-mouse antibodies were from Silenus Laboratories Pty. 
Ltd. (Melbourne, Australia). 
mAbs 
The preparation and tissue specificity of the Mel 3 antibody has been de- 
scribed in detail elsewhere (44, 45). Detailed analysis of the epitope recog- 
nized by Mel 3  revealed this to be in the sugar sequence, GalNAc  1-4 
(NeuAcet2-8NeuAcct2-3)Gall~l-4Glcl~l-lCer,  and the antibody binds to the 
gangliosides GD2, GD3, GT3, and GQlb but not to other gangliosides such 
as GMI, GM2, GM3, GDIa, GDlb, and GTlb (17). The mAb is an IgMk. 
The anti-~2 microglobulin rnAb, HB28,  was a gift from Dr.  Heddy Zola 
(Flinders Medical Centre,  Adelaide, Australia).  The CA2 antibody was 
raised by conventional fusion after immunization with activated human T 
lymphocytes and was selected for its ability to inhibit lysis of tumor target 
cells by activated lymphocyte killer cells by a method described elsewhere 
(7). The mAb, an IgMk,  immunoprecipitated a glycoprotein heterodimer 
of 170/85  kD from peripheral blood mononuclear cells and details of its 
specificity have been given elsewhere (5). A complete list of  anti-melanoma 
antibodies of every isotype that we have tested for inhibition of melanoma 
cell attachment and others kindly donated from several laboratories has been 
given elsewhere (44). None of these anti-glycoprotein mAbs affected adhe- 
sion. In the present experiments, the Nu4B mAb (from Dr. H. Koprowski, 
Wister Institute, Philadelphia, PA) was used routinely as a control. 
Preparation of Synthetic Peptides and 
Radiolabeled Peptides 
The peptides GRGDSP, KYGRGDSP, and GRGESP were synthesized on 
a peptide synthesizer (model 430A; Applied Biosystems, Inc., Foster City, 
CA) by a modified Merrifield tBoc solid-phase peptide chemistry procedure 
(2). On completion of each synthesis, the crude peptide was cleaved from 
the resin support by treatment with hydrogen fluoride (95% liquid HF/5% 
anisole, 0°C for 30 rain) and purified by gel-permeation chromatography 
on a Biogel P2 column (1  x  100 cm) in 0.5 M aqueous acetic acid. 
The peptide KYGRGDSP (150 I.tg) was mixed with 1 IICi 12~I and in- 
cubated at room temperature for 12 min with Iodobeads as described by the 
manufacturer. The free 125I was fractionated from bound 125I on a 35-ml 
Biogel  I>2  Column (Bio-Rad Laboratories,  Richmond, CA) equilibrated 
with  25  mM  NaOH.  The  fractions  containing  radiolabel  were  further 
purified by reverse-phase HPLC on a gradient system (model 334; Beckman 
Instruments, Inc., Fullerton, CA) coupled to a variable wavelength detector 
(model 163; Beckman Instruments, Inc.) set at 220 nm and a radioisotope 
detector (model 170; Beckman Instruments, Inc.) connected in series. Sam- 
ples were chromatographed on an Ultrasphere C18 column (4.6  x  150 nun) 
with a gradient from 10 to 50%  acetonitrile in phosphate buffer (I0 mM, 
pH 7.0) over a duration of 10 min at a flow rate of 1 ml/min. The retention 
time of unlabeled peptide was 8.5  min,  and  that of the labeled peptide 
12 rain. 
Attachment and Detachment  Assays 
Fibronectin was purified from human plasma by affinity chromatography on 
gelatin-Sepharose 4B (Pharmacia Fine Chemicals, Inc., Uppsala, Sweden) 
as described by Ruoslahti et al. (38); the purity and yield were then deter- 
mined by SDS-PAGE with Coomassie Blue staining and by a protein assay 
(Bio-Rad Laboratories).  The fibronectin was added to the wells of flat- 
bottomed  microtiter plates  (Flow  Laboratories,  Inc.,  McLean,  VA)  as 
0.1 mg/ml for 2 h at 25°C and the wells were washed twice with PBS and 
twice with medium. LiBr melanoma cells from subconfluent cultures were 
resuspended in RPMI 1640 medium containing 0.2 % BSA (Sigma Chemi- 
cal Co.) to l06 cells/ml. To each of the fibronectin-coated wells was added 
100 ~tl of the cell suspension together with the antibody or peptide being 
tested (10 I~l) and the plates were incubated for 2 h at 37°C in 5% CO2 be- 
fore assay. Detachment assays were performed in essentially the same way 
but in these tests the cells were incubated alone for 2 h at 37°C to enable 
attachment, then the agents under test were added in a volume of 10 ~tl and 
the cells incubated for a further 30 min. 
A colorimetric assay modified from Chong and Parish (14) was used to 
quantitate the attached cells. After the period allowed for detachment, the 
nonattached cells were thrown off and  residual cells were stained with 
0.25%  (wt/vol) Rose Bengal dye (Koch-Light Ltd., London, England) in 
PBS for l0 min at room temperature. Excess dye was thrown off and the 
plate inverted to drain. The wells were then washed two times in PBS and 
the stain released by adding 100 I.tl/well of 50% ethanol in PBS. Released 
dye was quantified as absorbance at 570 nm on a microplate reader (Dy- 
natech Laboratories Inc., Alexandria, VA), blanked against a well contain- 
ing only medium, and the percent inhibition of attachment and percent 
detachment were calculated from the OD570 values of test vs. control wells. 
A  series of preliminary experiments demonstrated that the OD570 values 
were linear for cells plated at 103-105 cells/well, and in every experiment 
triplicate wells were used for each test substance; the SDs of  these triplicate 
values were generally very small. 
Radioligand Binding  Assay 
LiBr cells from subconfluent cultures were harvested, washed, and  re- 
suspended in cold incubation buffer (Hanks' balanced salt solution IHBSS], 
1.6 mM CaCl2,  10 mM NAN3, 5 ~tg/ml cytochalasin  B, 0.1% BSA), pH 7.2, 
to 4  x  106 cells/100 Ixl. 100 1~1 suspended cells were incubated at 4°C, 2 h 
with 10 I.tM ~2~I-GRGDSP ±  1 mM GRGDSP in the presence or absence 
of the mAh under test. In a series of preliminary experiments, various con- 
centrations of Mel 3 or control antibodies were preincubated with the cells 
for various times on ice, at room temperature, or at 37°C before performing 
the binding assay (see Results). Bound ligand was separated from free by 
filtration through GF/C filters (Whatman, Inc., Clifton, NJ) presoaked for 
18 h in 20% hlotto (20% milk powder in PBS), using a filtration manifold 
(Millipore Corp., Bedford, MA). The filters were then washed extensively 
with HBSS and counted for cpm in a gamma counter (Packard Instrument 
Co.,  Downers Grove, IL).  In every assay,  each value was calculated as 
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ence of excess cold peptide from the mean of triplicates without cold; 
the SD of replicates was generally <10% of the specific binding. An ex- 
cess of the control peptide GRGESP did not reduce the binding of ~2~I- 
GRGDSP. 
Immunoprecipitation and Western Blot Analysis 
To analyze receptor proteins coprecipitated by the Mel 3  antibody that 
specifically binds gangliosides,  108  LiBr melanoma cells were lysed in 
Triton X-100 buffer and the clarified supernatant quantitated for protein 
content. A 50-~tl volume containing 100 ~g of protein was incubated over- 
night at 4°C with 200141 Sepharose 4B beads covalently coupled to the Mel 
3 antibody. The beads were washed three times in PBS and boiled in non- 
reducing buffer. The supernatant was then boiled in reducing buffer and 
subjected to electrophoresis in 7.5% SDS-polyacrylamide gels; 100 I.tg of 
total lysate was run in an adjacent track. At the completion of the run the 
immunoprecipitated proteins and total  proteins were electrophoretically 
transferred to nitrocellulose paper, a strip containing the high molecular 
weight markers (Bio-Rad Laboratories) excised for Coomassie Blue stain- 
ing, and the remaining tracks probed with rabbit antibodies (diluted  1: 
1,000)  specific for the Ilia I] chain of the vitronectin receptor on melanoma 
cells.  Bound  antibody was  detected by  an  indirect enzymoassay using 
horseradish peroxidase as described previously (25). 
Results 
The Effects of  Anti-GD2/GD3 and of  Synthetic 
Fibronectin Peptides  Are Synergistic in Preventing 
Attachment and Inducing Detachment by 
Melanoma Cells 
The mAb Mel 3 behaved in a similar way to other anti-GD2 
and  anti-GD3  antibodies  in preventing  the  attachment of 
melanoma cells to fibronectin-coated substrates, and also to 
dishes coated with laminin, fibrinogen, or thrombospondin 
(Lucas,  C.  M.,  unpublished  observations).  In addition,  it 
was found that Mel 3 caused rapid detachment of melanoma 
cells  that  were  already  attached  to  fibronectin  (data  not 
shown). It has been shown by others that the synthetic pep- 
tide GRGDSP, but not GRGESP, prevents spreading on and 
causes detachment from fibronectin substrate by a number 
of human and mouse cell types (18, 46).  This was shown 
also to be the case for the human melanoma cell line LiBr. 
We found that GRGDSP at 200 Ixg/ml (300 ~tM) specifcally 
prevented  50%  of  newly  plated  cells  from  attaching  to 
fibronectin,  and at 50  pg/ml (75  ~tM)  specifically caused 
detachment of 50% of cells that had been allowed to attach to 
a fibronectin substratum for 2 h before addition of GRGDSP 
or the control peptide (Figs. 1 and 2). The above experiments 
present data from trials carried out with cells in serum-free 
medium supplemented with 2 mg/ml BSA. Essentially simi- 
lar data were obtained in the presence of 5 or 10% FCS but 
higher concentrations of mAb or peptide were required and 
the  majority of experiments were performed with  defined 
serum-free medium. 
Used alone, Mel 3 prevented attachment to a titer of 1:30 
ascites and in separate experiments it was found that 100 Ixg/ 
ml of purified antibody caused half-maximal inhibition (not 
shown). In the presence of GRGDSP at 100 Ixg/ml, a concen- 
tration which by itself caused no inhibition of attachment, 
half-maximal inhibition was obtained at a dilution of 1:160 
of ascites (Fig.  1). The same synergistic effect between Mel 
3 and GRGDSP was seen in detachment assays (Fig.  2). 
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Figure 1. Inhibition of LiBr cell attachment to a fibronectin substra- 
tum in the presence or absence of various dilutions of Mel 3 ascites 
fluid with increasing concentrations of GRGDSP peptide. Cells in 
serum-free medium were incubated for 2 h in the presence of Mel 
3 antibody at the dilution shown or with an antibody to 2-micro- 
globulin (None). Nonattached cells were washed away, and stained 
residual cells quantitated  at an OD of 570  nm.  Cell attachment 
quantitated by the measurement of OD was converted to percent in- 
hibition calculated from controls. 
Ganglioside Codistributed with the Vitronectin 
Receptor Does Not Inhibit Binding of the Synthetic 
Peptide GRGDSP 
When melanoma cells are allowed to attach and spread onto 
plastic or fibronectin substrate, there is a rapid redistribution 
of the complex gangliosides,  and GD2,  at least,  becomes 
preferentially localized into microprocesses that make direct 
contact  with  the  fibronectin  substrate  (10).  We have con- 
firmed this observation at the level of light microscopy by 
staining  with  Mel  3,  and  have shown that  this  antigen  is 
also left behind in focal attachment processes after removal 
of the cells from the coverslip (data not shown). In addition, 
Cheresh et al. (13) have shown that the vitronectin receptor 
on human melanoma cells exists as a  functional  complex 
with  a  GD2  ganglioside;  thus,  the  antigens  were demon- 
strated to colocalize in  focal adhesion plaques as demon- 
strated by double-label transmission EM and indirect immu- 
nofluorescence, and purification of the vitronectin receptor 
on affinity columns caused copurification of GD2. We have 
found that the  Mel  3  antigen is also physically associated 
with the vitronectin receptor on LiBr melanoma cells by im- 
munoprecipitating  LiBr  lysates  with  Mel  3  and  probing 
Western blots of the immunoprecipitates with rabbit antibod- 
ies to the vitronectin receptor. Moreover, such specific physi- 
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Figure 2. Detachment of LiBr cells from a fibronectin substratum 
by Mel 3 and GRGDSP peptide. Cells were incubated for 2 h in 
serum-free medium to enable attachment and various concentra- 
tions of Mel 3 ascites and GRGDSP were added for a further 30- 
rain incubation. Attached cells were quantitated as in Fig. 1 legend 
and percent detachment calculated from controls. 
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cal association occurs on the cell membrane since capping 
with Mel 3 induces coclustering of the vitronectin receptor 
on these cells in two-color fluorescence experiments (data 
not shown). 
Because of this close spatial association it was possible 
that the Mel 3 antibody was interfering with cell attachment 
by steric hindrance of Arg-Gly-Asp-directed receptors. This 
was tested by measuring the ability of LiBr melanoma cells 
in  suspension  to bind  free GRGDSP  by  using  iodinated 
KYGRGDSP as a ligand.  Various times and temperatures 
were tested and the experiments reported were for binding 
carried out at 0°C for 120 min. With a fixed number of the 
cloned LiBr cells, the amount of peptide specifically bound 
varied considerably from experiment to experiment. When 
the cells were pretreated with Mel 3 under conditions that 
caused ganglioside clustering, however, there was a consis- 
tently observed two-to-threefold increase in the amount of 
peptide bound; the increased binding was specific in that it 
was displaceable with unlabeled GRGDSP but not with cold 
GRGESP (Table I). Also, the effect of Mel 3 was specific 
since  the  addition  of  an  antibody  to  132  microglobulin 
caused no increase in peptide binding, and another IgM anti- 
body,  CA2,  directed against  a  heterodimer of 170/85  on 
the surface of melanoma cells, which also causes detachment 
of  these cells from fibronectin substrata (5), served as a posi- 
tive control for these radioligand binding assays since addi- 
tion of CA2 completely inhibited binding of the peptide (Ta- 
ble I). Our favored interpretation of these data is that the Mel 
Table I. Inhibition of  Binding of  lodinated Synthetic Peptide 
KYGRGDSP to Melanoma Cells in Suspension by Different 
Antibodies 
Pretreatment  of cells  Specific cpm* 
Untreated  637  _+  330  (280-966) 
Anti-132 microglobulin  494  +  380  (244-934) 
Mel  3  2,661  +  1,796  (1,104-5,452) 
CA2  69  +  6  (62-74) 
Melanoma cells from the LiBr line were harvested from subconfluent cultures 
maintained in RPMI medium supplemented with 10% FCS. The harvested cells 
were washed and 4  ×  10  ~ cells in 100 Itl medium mixed with  10 p.l of 1:10 
ascites of the antibody under test in incubation buffer (BSS, 1.6 nM CaCI2, I0 
mM NAN3, 5 p.g/ml cytochalasin B, 0.1%  BSA). Cells with antibody were in- 
cubated at 37°C for 15 min, and cooled on ice; and  10 p.M (,'o150,000 cpm) 
~2~I-GRGDSP was added to each tube +  1 nM unlabeled GRGDSP; and bind- 
ing was allowed to occur for 180 min on ice. Specific cpm were determined 
as described in Materials and Methods. The results are tabulated from four in- 
dependent experiments. 
* Mean  :i:  SD.  Numbers  in parentheses  represent  the range of the results. 
3 antibody is causing clustering of the gangliosides, and that 
some such areas of high ganglioside concentrations would 
coincide with or be specifically associated with Arg-Gly- 
Asp-directed protein  receptors  and  effectively mimic  the 
redistribution of gangliosides into substrate-associated mi- 
croprocesses seen upon cell attachment to fibronectin. 
Discussion 
Since  the  discovery of specific glycoprotein cell  surface 
receptors for extracellular matrix proteins (6,  34,  35), the 
role of gangliosides has undergone a reappraisal. In the pres- 
ent study we present data substantiating the suggestion (10, 
12) that gangliosides do not bind directly to fibronectin but 
facilitate specific receptor-ligand binding  at  points  of at- 
tachment. 
The anti-ganglioside antibody used, Mel 3, binds to both 
GD2 and GD3 (17) and might therefore be expected to be 
very effective in preventing melanoma cell attachment, since 
antibodies individually directed against GD2 or GD3 are ad- 
ditive in their effect (12).  Nevertheless, when used together 
with the synthetic peptide GRGDSP in detachment assays, 
the effect on melanoma cell attachment was clearly synergis- 
tic.  These data  suggest that gangliosides  and  the  specifc 
receptors for the cell attachment sequence of fibronectin are 
operating at distinct but related levels in the attachment pro- 
cess. In this regard, it is of interest that, in similar assays per- 
formed with the CA2 antibody which identifies a glycopro- 
tein molecule and also prevents cell attachment to fibronectin 
(5), the addition of synthetic peptide was additive whereas 
the mAbs CA2 and Mel 3 were synergistic in causing detach- 
ment (Burns, G. E, and C. M. Lucas, unpublished observa- 
tions). Radiolabeled peptide binding assays carried out with 
melanoma cells in suspension indicated a possible mecha- 
nism of action for the gangliosides. We have shown previ- 
ously (45)  that melanoma cells maintained in  suspension 
exhibit reduced levels of gangliosides on their surface mem- 
brane.  As they reattach, the cells redistribute the ganglio- 
sides into the microprocesses that make direct contact with 
extracellular matrix  proteins  (10)  and  these  are  also  laid 
down in the adhesion plaque (11). Treatment of melanoma 
cells with anti-ganglioside antibodies prevents this redistri- 
bution of gangliosides to the basal surface causing the micro- 
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al. (12) have recently demonstrated that anti-ganglioside an- 
tibodies effectively prevented the attachment of melanoma 
cells to solid substrates of synthetic hexapeptides containing 
the Arg-Gly-Asp sequence, and that such peptides were not 
bound directly by melanoma gangliosides separated on thin 
layer chromatograms. The same group (12) also found that 
mAbs directed to gangliosides on tumor cells failed to induce 
significant capping of the antigen. We have observed, how- 
ever, that certain antigens are rapidly synthesized as they are 
capped, and that capping is masked by the constant redistri- 
bution of newly produced antigen unless cyclohexamide is 
included during the capping process (Burns, G. E, unpub- 
lished observations), and we have found that the Mel 3 anti- 
body caused prominent clustering of the surface ganglio- 
sides. Hence, the simplest interpretation of our binding data 
is that the anti-ganglioside antibody, which is of IgM iso- 
type, causes sufficient clustering of gangliosides in localized 
areas to produce artificial processes with an electrostatic en- 
vironment conducive to ligand binding. Because such bind- 
ing is not localized to microprocesses on the basal surface 
of the cell, attachment as such does not ensue, but we would 
predict that other events consequent upon  specific ligand 
binding (42) would be observed. We are currently attempting 
to isotype switch the Mel 3 hybridoma to determine whether 
IgG  antibodies  with  the  same  specificity require  further 
cross-linking to produce the same effect. 
The physical relationship between the ganglioside GD2 
and Arg-Gly-Asp-directed receptors on the surface of mela- 
noma cells has recently been the subject of study by Cheresh 
et al. (13). Immunostaining with antibodies to the vitronectin 
receptor and to GD2 revealed association of  the two antigens, 
and affinity purification of the vitronectin receptor in the 
presence of Ca  ++ enabled copurification of GD2.  We have 
confirmed these results by demonstrating biochemical coas- 
sociation after immunopurification in the opposite direction, 
whereby immunoprecipitation of GD2 and GD3 by the Mel 
3 antibody coprecipitated vitronectin chain antigen as de- 
tected by Western blotting (data not shown). That the gan- 
glioside-receptor complex is stable on the cell membrane 
was  illustrated  in  two-color  fluorescent  staining  studies, 
where it was shown that ganglioside clustering induced by 
the  Mel  3  antibody  also  caused  colocalization  of  the 
vitronectin receptor.  Hence, both components of the com- 
plex appear to migrate together within the membrane, per- 
haps suggesting that the fluidity of the membrane ganglio- 
sides may provide a mechanism for the rapid redistribution 
of receptor proteins during attachment.  The  formation of 
such ganglioside-receptor clusters induced by Mel 3 would 
also explain the increased attachment of synthetic peptide 
seen with melanoma cells maintained in suspension. 
The  role  of  gangliosides  is  clearly  of  more  general 
significance than the binding of extracellular matrix pro- 
teins. The mAb, Mel 3, inhibited cytolysis of melanoma cells 
by cytotoxic lymphoc3,tes by preventing conjugate formation 
(44), perhaps indicating a role for gangliosides in cell-cell 
adhesive processes; in support of this rat macrophages have 
a membrane receptor for gangliosides (36). Also, while the 
Mel 3 antibody alone had no effect on cell viability, it in- 
hibited by 50% colony formation in agar by anchorage-de- 
pendent melanoma cells (Burns, G. E, and J. A. Werkmeis- 
ter, unpublished observations), an event which is unaffected 
by Arg-Gly-Asp-containing peptides (20).  Gangliosides have 
also been implicated in a number of  cell types in such diverse 
receptor-mediated processes as the binding of various growth 
factors (4, 23) and the binding of lipopolysaccharide (8), var- 
ious bacterial toxins (15, 43), viruses (26), thyroid stimulat- 
ing hormone (1), transferrin (28),  and interferon (3).  With 
the identification of specific glycoprotein receptors for many 
of these factors, it is now becoming apparent that the role of 
gangliosides is that of an accessory molecule to facilitate 
binding or to modulate receptor function rather than func- 
tioning themselves as specific receptors. Whether or not the 
gangliosides simply confer a charged environment conduc- 
ive to ligand binding or are involved in the regulation of bio- 
chemical events such as receptor phosphorylation (9) awaits 
further study. 
The present report in describing synergy between an mAb 
to gangliosides and synthetic peptides containing the cell- 
binding region of fibronectin in preventing melanoma cell at- 
tachment has immediate practical implications. It has been 
known for some time that preventing cells from adhering and 
spreading  can  interfere  with  their  growth  in  vitro  (16). 
Houghton et al. (19) reported some success in treating pa- 
tients with malignant melanoma with an antibody to the gan- 
glioside GD3. Attempts at treatment with other anti-mela- 
noma mAbs of different specificity have been less successful, 
and it was suggested that the peculiar success of  this antibody 
could be attributable to the fact that it was of IgG3 isotype 
and particularly effective in mediating complement- and cell- 
mediated cytotoxicity  (19). This interpretation was made less 
tenable by a recent report (22)  of treatment with a human 
mAb to GD2  inducing regression of cutaneous malignant 
melanoma since the antibody used was of IgM isotype and 
would not mediate cell-mediated cytotoxicity. A  comple- 
ment-mediated effect for these antibodies remains a possibil- 
ity but it is probably significant that the only recorded suc- 
cesses in this area are with anti-ganglioside antibodies. In 
support of  alterations in the adhesive properties of melanoma 
cells being responsible for successful treatment is the finding 
that injection of the synthetic peptide GRGDS together with 
murine melanoma cells dramatically inhibited the formation 
of experimental lung metastasis in mice (20). Our findings 
reported here  suggest that future strategies  should incor- 
porate  treatment with  anti-ganglioside mAb  and  peptide 
given together. 
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